$0.03
0.00%
Nasdaq, Apr 21, 08:12 pm CET
ISIN
US36338D1081
Symbol
GRTX
Sector
Industry

Galera Therapeutics Inc Stock price

$0.03
-0.01 28.57% 1M
-0.04 63.82% 6M
-0.02 45.41% YTD
-0.17 87.40% 1Y
-1.92 98.71% 3Y
-11.48 99.78% 5Y
-11.98 99.79% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.00 3.85%
ISIN
US36338D1081
Symbol
GRTX
Sector
Industry

Key metrics

Market capitalization $1.89m
Enterprise Value $149.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.15m
Free Cash Flow (TTM) Free Cash Flow $-12.15m
Cash position $8.29m
EPS (TTM) EPS $-0.35
Short interest 5.28%
Show more

Is Galera Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Galera Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Galera Therapeutics Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Galera Therapeutics Inc:

Hold
100%

Financial data from Galera Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
92% 92%
-
-0.02 -0.02
92% 92%
-
- Selling and Administrative Expenses 14 14
37% 37%
-
- Research and Development Expense - -
-
-
-14 -14
70% 70%
-
- Depreciation and Amortization 0.02 0.02
92% 92%
-
EBIT (Operating Income) EBIT -14 -14
70% 70%
-
Net Profit -19 -19
68% 68%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galera Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galera Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 months ago
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.

Company Profile

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Head office United States
CEO J. Sorensen
Employees 3
Founded 2009
Website www.galeratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today